Neuroscientific Biopharmaceuticals Ltd. · ASX:NSB
Neuroscientific Biopharmaceuticals — Westar Capital Investor Evening (August 2020)
24 slides from Neuroscientific Biopharmaceuticals's conference presentation, Aug 26, 2020
Slide 1: NeuroScientific to Present at Westar Capital Investor Evening
For personal use only ASX ANNOUNCEMENT NeuroScientific to Present at Westar Capital Investor Evening Perth, Australia; 26 August 2020. NeuroScientific Biopharmaceuticals Ltd ASX: NSB (“NeuroScientific” or ”the Company”) is pleased to announce that the Company’s Chairman, Mr Brian Leedman will be mak
Slide 2: Novel Drug Therapies for Neurodegenerative Conditions
For personal use only NOVEL DRUG THERAPIES FOR NEURODEGENERATIVE CONDITIONS
Slide 3: Disclaimer
For personal use only ' ,6& /$ ,0 (5 The purpose of the presentation is to provide an update of the business of NeuroScientific Biopharmaceuticals Ltd (“NeuroScientific”, or “the Company”). These slides have been prepared as a presentation aid only and the information they contain may require furthe
Slide 4: Corporate Overview
For personal use only CORPORATE OVERVIEW • Completed IPO listing on the ASX July 2018 • Lead candidate funded through to completion of Phase I in primary indication • Core strategy: “pipeline in a product” (a) Neurodegenerative indication CNS; ASX code NSB most advanced in Alzheimer’s disease Shares
Slide 5: Since ASX Listing: Building Shareholder Value
For personal use only Further positive data Multiple Sclerosis SINCE ASX LISTING Myelination Model Building shareholder value Pre-IND safety & tox program 75% complete Positive data Multiple Sclerosis Myelination Model Positive data Glaucoma Pig Neuroprotective Model effects in mouse CVN Positive da
Slide 6: Leadership Team
For personal use only LEADERSHIP TEAM , MBA Co-founder of ResApp Health 14+ years experience Founding director of 20 years’ experience in Ltd (ASX.RAP), Imugene Ltd commercialising medical Actinogen Medical corporate advisory and (ASX:IMU) and Oncosil Ltd devices and pharmaceuticals (ASX:ACW) an adv
Slide 7: Treatment Markets with Unmet Need
For personal use only TREATMENT MARKETS WITH UNMET NEED ALZHEIMER’S DISEASE OPTIC NERVE CONDITIONS 48M people globally 5% of population have dementia suffer vision loss due to 70% of dementias damaged optic nerve Alzheimer’s disease 60M people US $818B global affected by Glaucoma economic burden US$
Slide 8: Lead Candidate: EmtinB
For personal use only LEAD CANDIDATE: EMTINB NOVEL Modeled on Metallothionein (MT-II) - a well known neuroprotective and neurogenerative compound, with EmtinB showing superior drug properties Binds LRP-1 receptors – novel Mechanism of Action (MOA) Stops cell death & stimulates regeneration VAL
Slide 9: Evolution of EmtinB
For personal use only EVOLUTION OF EMTINB MT-II STRUCTURE EmtinB Peptide EmtinB Peptide Dendrimer β-domain α-domain 61 amino acid length 14 amino acid length Synthesised as a tetrameric Binds divalent metal ions Isolated from the β-domain of dendrimer Difficult to manufacture MT-II prote
Slide 10: Preclinical Data
For personal use only PRECLINICAL DATA Consistent pro-survival and regeneration effect in multiple neurodegeneration models
Slide 11: EmtinB Scientific Data: Neuron Survival
For personal use only EMTINB SCIENTIFIC DATA Increases survival of damaged neurons in various regions of central nervous system CORTEX HIPPOCAMPUS HIPPOCAMPUS: ALZHEIMER’S MODEL
Slide 12: EmtinB Scientific Data: Axonal Regeneration
For personal use only EMTINB SCIENTIFIC DATA Increases axonal regeneration in various regions of central nervous system CORTEX HIPPOCAMPUS HIPPOCAMPUS: INJURY MODEL SPINAL CORD: INJURY MODEL
Slide 13: EmtinB Scientific Data: Myelination
For personal use only EMTINB SCIENTIFIC DATA Preclinical functional studies Myelination: Increased the number of oligodendrocytes MULTIPLE SCLEROSIS MODEL EmtinB, A2B5+ 875% Oligodendrocytes are support cells that create the EmtinB, MAG+ 607% myelin sheath that insulate axons; demyelination result
Slide 14: EmtinB Scientific Data: Alzheimer's Animal Model
For personal use only EMTINB SCIENTIFIC DATA Preclinical functional studies ALZHEIMER’S ANIMAL MODEL Crosses the blood brain barrier within 1-hour of being administered Plasma profile: detected over 24-hours Slowed progression of Alzheimer’s disease (memory impairment) by >80% in Alzheimer’s a
Slide 15: Preclinical Data: Ophthalmology
For personal use only PRECLINICAL DATA Ophthalmology
Slide 16: Supporting Ocular Data: Regenerating the Optic Nerve
For personal use only SUPPORTING OCULAR DATA Regenerating the optic nerve No Treatment cut RAT TRANSECTION MODEL EmtinB precursor compound (metallothionein-II): Treatment Stimulated regeneration of the optic nerve by up to 1000um (>250% vs non-treated) Axonal regeneration was evident well beyond
Slide 17: EmtinB Ocular Data: Tissue Penetration
For personal use only EMTINB OCULAR DATA Preclinical tissue penetration Retina, 6-hours Optic nerve head, 6-hours OCULAR TISSUE PENETRATION IN RABBITS Significant concentrations of EmtinB (fluoro-labelled) detected at 3-h, 6-h, and 9-h after single dose EmtinB passed through the ocular membranes
Slide 18: EmtinB Ocular Data: Glaucoma Pig Model
For personal use only EMTINB OCULAR DATA Neuroprotection and regeneration of the optic nerve GLAUCOMA PIG MODEL LQFUHDVH EmtinB demonstrated neuroprotection in glaucoma IOP pig model High intraocular pressure pig model is the closest experiment to replicate severe human glaucoma pathology; posit
Slide 19: EmtinB Ocular Data: Optic Nerve Biomarkers
For personal use only EMTINB OCULAR DATA Neuroprotection and regeneration of the optic nerve NFHp Non-treatment NFHp EmtinB GLAUCOMA PIG MODEL Disruption of cytoskeleton proteins and neurofilaments in neuronal tissue are used as markers for axonal damage Tubulin Non-treatment Tubulin EmtinB Emti
Slide 20: Partnerships & Collaborations
For personal use only PARTNERSHIPS & COLLABORATIONS Research & Manufacturing Partners
Slide 21: Business Model – Outlicensing at Clinical Stage
For personal use only BUSINESS MODEL – OUTLICENSING AT CLINICAL STAGE Neuroscience and Neurodegenerative Diseases hold the most promise for medical breakthroughs in the next decade Drug candidates with multiple treatment indications, such as EmtinB, are in-demand assets for Big Pharma Number o
Slide 22: EmtinB Development Schedule
For personal use only EMTINB DEVELOPMENT SCHEDULE 2020 2020 2020 2020 2021 2021 2021 2021 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Neurodegenerative indications Complete preclinical safety & No toxicity in dose levels 60x toxicology studies higher than planned clinical dose Complete GMP manufacturing Assuming no fur
Slide 23: Summary Overview
For personal use only SUMMARY OVERVIEW NEUROSCIENTIFIC BIOPHARMACEUTICALS LTD (ASX: NSB) • Drug development company with an advanced preclinical lead drug candidate called EmtinB; funded through to completion of Phase I in primary treatment indication • EmtinB targets LRP-1 expressed on the outside
Slide 24: Novel Drug Therapies for Neurodegenerative Conditions
For personal use only NOVEL DRUG THERAPIES FOR NEURODEGENERATIVE CONDITIONS
NeuroScientific Biopharmaceuticals — Westar Capital Investor Evening (August 2020) on 6ix